Latest press releases Jul 26 2022 MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH May 12 2022 MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa May 09 2022 MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab View All News View All Press Releases + Upcoming events Sep 12 - Sep 14 2022 HC Wainwright 24th Annual Global Investment Conference Nov 14 - Nov 15 2022 Guggenheim 4th Annual Immunology and Neurology Day Nov 15 - Nov 17 2022 Jefferies 2022 London Healthcare Conference View All Events View All Events + Corporate presentations Corporate presentation - July 2022 View All Presentations View All Presentations + IR contact details Dr. Atif Khan, Director of Strategic Planning and Projects e: ir@moonlaketx.com
Jul 26 2022 MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
May 12 2022 MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
May 09 2022 MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
MoonLake
MoonLake
